According to this integrated model, NOTCH1-mutated patients belong to an intermediate-risk group that accounts for approximately 15–20% of newly diagnosed CLL and shows a 10-year survival of 37%. This evidence concerns the gene NOTCH1 and B-cell chronic lymphocytic leukemia.